In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab

BACKGROUND: Eribulin mesylate (eribulin) is a first-in-class halichondrin B-based microtubule dynamics inhibitor. To compare the anti-angiogenic activity of eribulin to that of bevacizumab, we compared tumour vessel remodelling and reoxygenation between the two agents. METHODS: Patients with advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Shigeto, Saeki, Toshiaki, Takeuchi, Hideki, Shigekawa, Takashi, Yamane, Tomohiko, Kuji, Ichiei, Osaki, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891505/
https://www.ncbi.nlm.nih.gov/pubmed/27140309
http://dx.doi.org/10.1038/bjc.2016.122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891505/
https://www.ncbi.nlm.nih.gov/pubmed/27140309
http://dx.doi.org/10.1038/bjc.2016.122

Ejemplares similares